论文部分内容阅读
目的探讨辛伐他汀对2型糖尿病合并冠心病患者血同型半胱氨酸(Homocysteine,Hcy)的影响。方法:随机选取2型糖尿病无冠心病患者16例;2型糖尿病合并冠心病患者45例。其中合并冠心病组分为辛伐他汀非治疗组16例,治疗组18例。分别治疗12周,治疗前后均检测生化及Hcy等指标。结果:2型糖尿病合并冠心病患者的Hcy水平较无冠心病组高,辛伐他汀治疗12周后3组患者的甘油三酯(Triglyceride,TG)、总胆固醇(Total chloesterol,TC)和Hcy水平均较治疗前降低(P<0.05),高密度脂蛋白胆固醇(High density lipoprotein cholesterol,HDL-c)升高有显著意义(P<0.01)。结论:辛伐他汀降低TC,升高HDL之外,可以通过减低Hcy水平来发挥其抗动脉粥样硬化作用。
Objective To investigate the effect of simvastatin on blood homocysteine (Hcy) in type 2 diabetic patients with coronary heart disease. Methods: Sixteen patients with type 2 diabetes without coronary heart disease were selected randomly. 45 patients with type 2 diabetes mellitus complicated with coronary heart disease. Among them, 16 cases were treated with simvastatin and 18 cases were treated with coronary heart disease. Respectively for 12 weeks, before and after treatment were measured biochemical and Hcy and other indicators. Results: The Hcy levels in patients with type 2 diabetes mellitus complicated with coronary heart disease were higher than those without coronary heart disease. Triglyceride (TG), total cholesterol (TC) and Hcy levels were significantly higher in the 3 groups after simvastatin treatment for 12 weeks (P <0.05), and high density lipoprotein cholesterol (HDL-c) increased significantly (P <0.01). Conclusion: Simvastatin can reduce TC and increase HDL, and reduce the Hcy level to exert anti-atherosclerotic effects.